Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Vascular Calcification 1Neoplasm Metastasis 1Kidney Diseases 1Hyperparathyroidism 1Chronic Kidney Disease-Mineral and Bone Disorder 1Bone Diseases 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × etelcalcetide hydrochloride × Head & Neck × Clear all
NCT03960437 2023-09-21

Parsabiv-MBD

Columbia University

Phase 2 Completed
22 enrolled 14 charts
GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡